A Pharmacodynamically-Guided Dose Escalation Phase I Study to Assess the Safety of AFM13 (Recombinant Antibody Construct Against Human CD30 and CD16A) in Patients With Refractory and/or Relapsed Hodgkin Lymphoma.

Trial Profile

A Pharmacodynamically-Guided Dose Escalation Phase I Study to Assess the Safety of AFM13 (Recombinant Antibody Construct Against Human CD30 and CD16A) in Patients With Refractory and/or Relapsed Hodgkin Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs AFM 13 (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; First in man
  • Sponsors Affimed Therapeutics
  • Most Recent Events

    • 21 May 2015 According to an Affimed Therapeutics media release, results from this trial were published in the journal Blood.
    • 09 Dec 2014 Results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
    • 10 Apr 2014 Results have been presented at the 105th Annual Meeting of the American Association for Cancer Research according to an Affimed Therapeutics media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top